Please assess the completion status of the following clinical trial:

Trial Title: Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admitted to Scripps Mercy Trauma Service~* ≥18 Years old~* Stratified to either Significant or Highest risk of VTE by ACCP guidelines~Exclusion Criteria:~* Estimated Injury Severity Score (ISS) ≤9~* Likely to be discharged before hospital day 7~* Systemic coagulopathy defined with an International Normalized Ratio (INR) of ≥1.2~* Body Mass Index (BMI) \>40~* Likely to Survive for \<7 Days~* Pregnancy~* Evidence of renal insufficiency (Cr ≥1.3)~* Delayed transfer to this facility (\>24 hrs)~* Prisoners

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5000 Units unfractionated Heparin Q 8 hr (Type: EXPERIMENTAL): Low Dose Unfractionated Heparin (5000 Units) given every eight hours until primary or secondary outcome measure reached, discharge, or \>30 days on trauma service.
- 30mg enoxaparin Q12 hr (Type: ACTIVE_COMPARATOR): Randomly assigned trauma patients to receive Low Molecular Weight Heparin (30mg enoxaparin) given subcutaneously every twelve hours until primary or secondary outcome measure reached, discharge, or \>30 days on trauma service.

Based on this trial design, predict the completion outcome and termination type (if applicable).